The Identification of Novel Prognostic Markers in Melanoma
Recruitment status was: Recruiting
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Novel Prognostic Markers in Melanoma: a Protocol for the Analysis of Paraffin-embedded Tumour Samples|
- Given that the nature of the research is qualitative, there is no primary outcome measure.
|Study Start Date:||December 2008|
|Estimated Study Completion Date:||December 2009|
|Estimated Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
|Malignant melanoma tumour tissue|
Benign pigmented lesions & other skin cancers
Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
Background - The Royal Marsden Hospital and the Institute of Cancer Research constitute the largest comprehensive cancer centre in Europe. In addition to an in-house drug development program, phase I - phase III clinical trials of novel anti-cancer agents are hosted. In order to investigate the optimal use of novel molecularly targeted agents, access to clinical tumour samples is needed in order to determine which particular cancer type expresses a molecular "signature" that may indicate potential therapeutic utility. Understanding such signatures should accelerate the registration of new drugs for routine cancer therapy; offering the potential of selecting those patients with tumour types most likely to benefit from therapy. Furthermore, new insights into disease biology may be gained.
Main research question/ objective - Are there features of primary melanoma or lymph node metastases that predict subsequent clinical outcome better than existing markers?
Please refer to this study by its ClinicalTrials.gov identifier: NCT01002560
|Royal Marsden NHS Foundation Trust|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Principal Investigator:||Professor Martin Gore||Royal Marsden NHS Foundation Trust|